Flubok regulatory update

Protein Sciences said FDA granted accelerated approval to an sBLA for Flublok seasonal influenza vaccine to prevent seasonal influenza infection in adults ages >=50 years. Flubok was approved in adults ages 18-49 years. The trivalent seasonal influenza vaccine is made with recombinant hemagglutinin antigens purified from cultured insect cells. ...